Breaking News Instant updates and real-time market news.

GALE

Galena

$0.00

(0.00%)

, RHHBY

Roche

$0.00

(0.00%)

10:29
05/17/18
05/17
10:29
05/17/18
10:29

Valeant, Gilead among many on FDA list of drugmakers 'gaming' generic entry

The FDA, working toward the Trump Administration's priority of advancing policies that increase competition as a way to help make drugs more affordable and improve access, has released a list of brand companies that it sees having created obstacles for generic developers in purchasing samples of their brand drugs. The FDA stated "We're making public a list of companies that have potentially been blocking access to the samples of their branded products. We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval. We often hear of these tactics when it comes to generic drug developer access to samples when the brand products are subject to limited distribution programs." Among the many drugmakers on the FDA's list are: Valeant (VRX), Pfizer (PFE), Biogen (BIIB), Insys Therapeutics (INSY), VIVUS (VVUS), Celgene (CELG), Bayer (BAYRY), Gilead (GILD), BioMarin (BMRN), Novelion Therapeutics (NVLN) - formerly Aegerion, Mallinckrodt's (MNK) Questcor, Shire (SHPG), Merck's (MRK) Cubist, Jazz Pharmaceuticals (JAZZ), Teva (TEVA), AstraZeneca (AZN), Acorda Therapeutics (ACOR), Mylan (MYL), Novartis (NVS), Roche (RHHBY) and Galena (GALE). Reference Link

GALE

Galena

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$77.25

-0.35 (-0.45%)

MYL

Mylan

$40.02

0.79 (2.01%)

ACOR

Acorda Therapeutics

$24.50

0.05 (0.20%)

AZN

AstraZeneca

$36.64

0.14 (0.38%)

TEVA

Teva

$20.99

0.1 (0.48%)

JAZZ

Jazz Pharmaceuticals

$162.35

1.24 (0.77%)

MRK

Merck

$59.36

-0.4 (-0.67%)

SHPG

Shire

$170.61

-2.55 (-1.47%)

MNK

Mallinckrodt

$15.79

0.22 (1.41%)

NVLN

Novelion Therapeutics

$4.32

0.05 (1.17%)

BMRN

BioMarin

$88.40

-1.03 (-1.15%)

GILD

Gilead

$67.50

-0.03 (-0.04%)

BAYRY

Bayer

$0.00

(0.00%)

CELG

Celgene

$80.47

-0.88 (-1.08%)

VVUS

VIVUS

$0.68

0.0221 (3.37%)

INSY

Insys Therapeutics

$7.27

0.16 (2.25%)

BIIB

Biogen

$277.68

-3.69 (-1.31%)

PFE

Pfizer

$35.67

-0.01 (-0.03%)

VRX

Ticker changed BHC

$22.17

0.08 (0.36%)

  • 17

    May

  • 18

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 25

    May

  • 30

    May

  • 31

    May

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

GALE Galena
$0.00

(0.00%)

RHHBY Roche
$0.00

(0.00%)

05/16/18
PIPR
05/16/18
NO CHANGE
PIPR
Piper survey shows growth in non-invasive prenatal test volumes
Piper Jaffray analyst William Quirk says his firm's annual survey of obstetricians and gynecologists suggests "significant" near-term growth in average-risk non-invasive prenatal test volume. This is good for Quest Diagnostics (DGX), Illumina (ILMN), LabCorp (LH), Natera (NTRA) and Roche (RHHBY), Quirk tells investors in a research note. Piper found that the number of doctors offering non-invasive prenatal tests to average risk patients increased to 59% in 2018 from 35% last year. Lack of reimbursement remains a barrier to more testing, but importantly, for the second year in a row, resistance to offering NIPT due to Medicaid and clinical data declined, Quirk adds.
05/10/18
05/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macy's (M) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Kimberly Greenberger citing its ongoing negative store-only comparable sales and continued decline in return on invested capital, or ROIC. 2. L Brands (LB) downgraded to Sell from Hold at Loop Capital with analyst Laura Champine saying the April same-store-sales result of 0% was driven by promotions, and merchandise margin was once again "down significantly." The analyst also cut her price target for the shares to $28 from $40. 3. Tableau (DATA) downgraded to Sell from Neutral at MoffettNathanson. 4. Roche (RHHBY) downgraded to Market Perform from Outperform at Bernstein with analyst Tim Anderson saying its model shows the slowest 5Y EPS growth among his 10 covered names. 5. Baker Hughes (BHGE) downgraded to Neutral from Buy at BofA/Merrill with analyst Timna Tanners citing the strong run in Baker Hughes shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.
05/10/18
JPMS
05/10/18
NO CHANGE
Target $185
JPMS
Overweight
Array BioPharma added to Analyst Focus List at JPMorgan
JPMorgan analyst Anupam Rama added Array BioPharma (ARRY) to his firm's Analyst Focus List as a growth strategy and reiterates an Overweight rating on the shares. The analyst lowered his price target for the stock to $18 from $19 after taking out MEK + I/O from his model. He believes, however, that Roche's (RHHBY) Phase 3 IMblaze370 trial failure was largely priced in. Rama recommends buying Array at current levels ahead of the "multiple" mid-year pipeline catalysts.
NVS Novartis
$77.25

-0.35 (-0.45%)

05/01/18
RBCM
05/01/18
NO CHANGE
RBCM
Sector Perform
Regeneron's Eylea faces strong competition from brolucizumab, says RBC Capital
RBC Capital analyst Kennen MacKay says yesterday's phase 3 presentation of data from Novartis (NVS) regarding the prospects of brolucizumab in wet age-related macular degeneration suggests that the treatment is strongly positioned vs. Regeneron's (REGN) Eylea. MacKay adds that Novartis intends to submit the Biologics License Applications for brolucizumab in December of this year, with expected launch in the second half of 2019. The analyst keeps his Sector Perform rating on Regeneron.
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
MYL Mylan
$40.02

0.79 (2.01%)

04/23/18
WELS
04/23/18
NO CHANGE
WELS
Market Perform
Mylan layoffs will led to questions, says Wells Fargo
Wells Fargo analyst David Maris acknowledges press reports that Mylan is laying off approximately 500 employees, or approximately 15% of its employees in Morgantown, Virginia. Investors will have questions when Mylan reports Q1 results about the layoffs and what Mylan means about the need to make the Morgantown plant less complex, Maris tells investors in a research note. He keeps a Market Perform on Mylan shares.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
ACOR Acorda Therapeutics
$24.50

0.05 (0.20%)

02/16/18
PIPR
02/16/18
UPGRADE
Target $37
PIPR
Overweight
Piper upgrades Acorda to Overweight on potential in Parkinson's
Piper Jaffray analyst Charles Duncan last night upgraded Acorda Therapeutics and raised his price target for the shares to $37 from $32. The analyst, based on diligence in the Parkinson's space, has "enhanced conviction" that Inbrija can be a $700M-$800M drug in the U.S. alone. He sees a "risk-reduced regulatory path" ahead in the U.S. and Europe. Acorda closed yesterday down 50c to $25.10.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
01/31/18
JANY
01/31/18
NO CHANGE
JANY
Neutral
Competitor Phase 3 'takes some shine off' Acorda Therapeutics, says Janney Capital
Janney Capital analyst Ken Trbovich notes that Sunovion Pharmaceuticals, a wholly owned U.S.-based subsidiary of Sumitomo Dainippon Pharma, reported positive top-line results from its Phase 3 trial of APL-130277 for treating OFF-rescue in Parkinson's Disease patients. While the respective Phase 3 studies were not head-to-head, it would appear APL-130277 may be the more potent OFF rescue treatment, with the trade-off being higher rates unpleasant side effects such as nausea and dizziness, the analyst notes. Trbovich believes this could take some of the luster off perceived M&A value of Acorda Therapeutics, but it is unlikely to eliminate interest. He reiterates a Neutral rating on Acorda Therapeutics' shares.
02/15/18
PIPR
02/15/18
UPGRADE
PIPR
Overweight
Acorda Therapeutics upgraded to Overweight from Neutral at Piper Jaffray
AZN AstraZeneca
$36.64

0.14 (0.38%)

04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.
03/14/18
HCWC
03/14/18
NO CHANGE
Target $6
HCWC
Buy
Advaxis drug unlikely culprit of patient death, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Advaxis (ADXS) to $6 from $23 after the FDA placed a clinical hold on the Phase 1/2 study investigating the combination of the company's axalimogene filolisbac and AstraZeneca's (AZN) durvalumab for the treatment of HPV-associated cervical and head and neck cancers. Based on its previous safety profile, axalimogene is unlikely to be the cause of death for this patient, Ramakanth tells investors in a research note. The analyst, however, notes that it would likely take several months before the FDA is able to reach a decision and lift the clinical hold. He anticipates a one-to-two quarter delay to the axal plus durva combination therapy program but keeps a Buy rating on Advaxis shares.
03/19/18
JEFF
03/19/18
UPGRADE
JEFF
Buy
AstraZeneca upgraded to Buy from Hold at Jefferies
Jefferies analyst Ian Hilliker upgraded AstraZeneca to Buy and raised his price target for the shares to 5,600p from 5,075p. The company is at a "turning point," Hilliker tells investors in a research note. He believes accelerating new product launches and improving margins should deliver over 20% core earnings growth in the mid-term. Recovering growth, driven by the underlying business warrants a "modest mid-term premium valuation," the analyst contends.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$20.99

0.1 (0.48%)

04/30/18
DBAB
04/30/18
NO CHANGE
Target $22
DBAB
Buy
Deutsche raises Valeant price target on extended Xifaxan exclusivity
The stay in the Xifaxan litigation between Valeant Pharmaceuticals (VRX) and Teva (TEVA) was recently extended to July 30, 2018 from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note. According to the court docket, the companies agreed to extend the stay "because the facts and circumstances that warranted a stay as of May 15, 2017 have not materially changed," Gilbert adds. He previously modeled Xifaxan exclusivity through 2024, but pushed that out one more year saying Teva "does not yet appear to have clarity on the path forward for its generic filing." The exclusivity extension to 2025 on Valeant's largest product pushes the analyst's price target for the shares to $22 from $20. The stock in midday trading is up 19c to $18.26. Gilbert looks forward to an update from Teva when the company reports on May 3 and continues to like the risk/reward for Valeant. He keeps a Buy rating on the shares.
04/27/18
JEFF
04/27/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine's Ingrezza can beat Q1 estimates, says Jefferies
Jefferies analyst Biren Amin says his firm's fifth proprietary survey on tardive dyskinesia reaffirms that Neurocrine Biosciences' (NBIX) Ingrezza is leading Teva's (TEVA) Austedo in market share for both moderate-severe and mild cases. The analyst thinks Ingrezza can modestly beat consensus estimates for Q1. He keeps a Buy rating on Neurocrine shares with a $105 price target.
05/07/18
FBCO
05/07/18
NO CHANGE
Target $23
FBCO
Outperform
Teva turnaround story appears generally on track, says Credit Suisse
Credit Suisse analyst Vamil Divan believes Teva's Q1 earnings were "solid" and sees his bullish thesis on the company as being on track. The analyst notes that the company's restructuring program is proceeding in line with its prior guidance and his expectations, if even a bit ahead of schedule. Divan reiterates an Outperform rating and $23 price target on the shares.
05/03/18
WELS
05/03/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva Q1 'just what investors wanted,' says Wells Fargo
Wells Fargo analyst David Maris believes this quarter is exactly the quarter investors wanted out of Teva, namely progress on the cost cutting and raised guidance on the back of a business that is still facing a significant decline given a tough U.S. generics environment and generic Copaxone pressures. The analyst reiterates an Underperform rating and $16.50 price target on the shares.
JAZZ Jazz Pharmaceuticals
$162.35

1.24 (0.77%)

05/15/18
WELS
05/15/18
NO CHANGE
WELS
Jazz Pharmaceuticals price target raised to $182 from $176 at Wells Fargo
Wells Fargo analyst David Maris maintained an Outperform rating on Jazz Pharmaceuticals and raised his price target to $182 from $176 on Jazz shares. The analyst also raised his 2018 EPS estimate to $13.00 from $12.91 after Jazz's beat and raise quarter, and raised his outer year Xyrem growth forecasts from 8% to 10% in 2019, from 6% to 8% in 2020 and from 4% to 5% in 2021, based on Xyrem's return to stronger growth in Q1. Maris concluded that he liked " the conservative balance sheet and potential for strategic deals, the current sales trends, and the focus on pipeline progress."
04/12/18
PIPR
04/12/18
NO CHANGE
Target $201
PIPR
Overweight
Jazz remains high conviction specialty pharma idea at Piper Jaffray
After surveying 25 physicians who treat a significant number of obstructive sleep apnea and narcolepsy patients, Piper Jaffray analyst David Amsellem believes peak U.S. sales potential for Jazz Pharmaceuticals' solriamfetol of at least $400M in the OSA/narcolepsy setting is realistic, "particularly given the sizable portion of patients who do not respond adequately to existing options." Solriamfetol helps position Jazz for annual double-digit EBITDA growth over the next several years, Amsellem tells investors in a research note. He calls Jazz one of his highest conviction specialty pharma ideas. The analyst reiterates an Overweight rating on the shares with a $201 price target.
05/01/18
RILY
05/01/18
NO CHANGE
Target $206
RILY
Buy
Jazz Pharmaceuticals named Alpha Generator Pick at B. Riley FBR
B. Riley FBR analyst David Buck named Jazz Pharmaceuticals his Alpha Generator Pick and keeps a Buy rating on the shares with a $206 price target. The analyst views the company's in-line product growth as attractive.
05/01/18
MZHO
05/01/18
NO CHANGE
Target $91
MZHO
Buy
Spark Therapeutics price target raised to $91 from $79 at Mizuho
Mizuho analyst Difei Yang raised her price target for Spark Therapeutics (ONCE) to $91 citing the priority review voucher sale to Jazz Pharmaceuticals (JAZZ) as well as "probability adjusted M&A premium." Spark is one of the highest-quality gene therapy companies, so it is reasonable to apply a conservative takeover premium to the stock's valuation, Yang tells investors in a research note. The analyst reiterates a Buy rating on the shares.
MRK Merck
$59.36

-0.4 (-0.67%)

05/17/18
WEDB
05/17/18
NO CHANGE
Target $53
WEDB
Outperform
Eiger BioPharmaceuticals price target raised to $53 from $36 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Eiger BioPharmaceuticals (EIGR) to $53 from $36 after the company expanded its licensing agreement with Merck (MRK) to include Hutchinson-Gilford Progeria Syndrome, or progeria, a fatal premature aging disease for which there are no approved drugs, after publication on April 24 in the Journal of the American Medical Association of Phase 2 results demonstrating a survival benefit -- after 2.2 years, only 1 of 27 lonafarnib-treated progeria syndrome patients died compared to 9 of 27 of untreated patients. In a research note to investors, Moussatos, who has an Outperform rating on shares, said that Eiger now has worldwide rights for progeria, HDV and all lonafarnib indications is a "game-changer" for the company.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
04/26/18
BMOC
04/26/18
NO CHANGE
Target $70
BMOC
Outperform
Merck price target raised to $70 from $65 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $70 and kept his Outperform rating, forecasting a "mixed to net-positive" Q1 earnings report. The analyst notes the focus will likely fall on the core Keytruda and Januvia franchises as he raises his peak sales estimate for the former to $13B from $12B after KN-189 data, which he expects to be further supported by discussions at ASCO.
SHPG Shire
$170.61

-2.55 (-1.47%)

04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
MNK Mallinckrodt
$15.79

0.22 (1.41%)

05/02/18
05/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alcoa (AA) initiated with a Buy at Jefferies. 2. Spotify (SPOT) initiated with a Buy at SunTrust. 3. Skyworks (SWKS) initiated with an Outperform at Baird. 4. Mallinckrodt (MNK) initiated with a Neutral at B. Riley FBR. 5. CatchMark Timber (CTT) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/18
MZHO
05/04/18
NO CHANGE
Target $13
MZHO
Neutral
Mallinckrodt likely to terminate jaundice program, says Mizuho
Mizuho analyst Irina Koffler expects Mallinckrodt to terminate its drug for severe jaundice after an FDA advisory panel recommended against approval. Termination could result in 15c-20c in earnings upside in 2018, Koffler tells investors in a research note. She views the news as a pipeline setback and keeps a Neutral rating on Mallinckrodt.
05/04/18
WELS
05/04/18
NO CHANGE
Target $15
WELS
Market Perform
Mallinckrodt price target lowered to $15 on stannsoporfin news at Wells Fargo
Wells Fargo analyst David Maris lowered his price target on Mallinckrodt to $15 from $17.50 after deciding to take stannsoporfin sales out of his model following the joint meeting of the FDA's GI Drugs Advisory Committee and Pediatric Advisory Committee, during which the panel overwhelmingly voted against the approval of stannsoporfin. He spoke with Mallinckrodt after the AdComm and the company said it is "disappointed" with the result and that a path forward for stannsoporfin will be evaluated to see if it makes sense to continue development, Maris noted. He maintains a Market Perform rating on Mallinckrodt shares.
05/09/18
LEHM
05/09/18
NO CHANGE
Target $12
LEHM
Underweight
Mallinckrodt price target lowered to $12 from $20 at Barclays
Barclays analyst Douglas Tsao lowered his price target for Mallinckrodt to $12 and keeps an Underweight rating on the shares. While Stannsaporfin was not expected to be a big product commercially, its failure to get the FDA panel vote raises questions on Mallinckrodt's "R&D acumen," Tsao tells investors in a research note. Further, the analyst believes uncertainty on Acthar is likely to persist.
NVLN Novelion Therapeutics
$4.32

0.05 (1.17%)

BMRN BioMarin
$88.40

-1.03 (-1.15%)

05/16/18
ADAM
05/16/18
INITIATION
Target $101
ADAM
Buy
BioMarin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated BioMarin with a Buy rating as she likes the setup heading into 2019. The analyst sees current risk levels skewed toward negative outcomes around its Pegvaliase PDUFA and hemophilia A gene therapy competitor data. She believes the gene therapy platform may be underappreciated. Gilson has a $101 price target on BioMarin shares.
05/07/18
LEER
05/07/18
NO CHANGE
Target $145
LEER
Outperform
BioMarin price target raised to $145 from $132 at Leerink
Leerink analyst Joseph Schwartz raised his price target to $145 from $132 to reflect new price assumptions for Valrox in hemophilia A following discussions with MEDACorp payor specialists. The analyst reiterates an Outperform rating on the shares.
04/26/18
JPMS
04/26/18
NO CHANGE
Target $127
JPMS
Overweight
BioMarin optimistic ahead of pegvaliase PDUFA date, says JPMorgan
The most noteworthy takeaway from BioMarin's Q1 update was the company's "very evident optimism" ahead of next month's pegvaliase PDUFA date, JPMorgan analyst Cory Kasimov tells investors in a research note. While the stock has been relatively stagnant for a prolonged period given a perceived lack of catalysts, the potential approval is one of two potential near-term drivers of sentiment leading up to critical Phase 3 readouts in 2019, Kasimov adds. He reiterates an Overweight rating on BioMarin shares with a $127 price target.
04/30/18
BERN
04/30/18
NO CHANGE
Target $92
BERN
Market Perform
BioMarin price target lowered to $92 from $97 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for BioMarin to $92 from $97 following quarterly results. The analyst reiterates a Market Perform rating on the shares.
GILD Gilead
$67.50

-0.03 (-0.04%)

05/02/18
MAXM
05/02/18
NO CHANGE
Target $89
MAXM
Buy
Gilead price target lowered to $89 from $94 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Gilead to $89 after the company's Q1 results missed consensus, driven by lower than expected HIV/HBV revenues. The analyst has also reduced his FY18 EPS view to $6.14 from $6.74 and revenue to $20.5B from $21.4B, adding that while CAR-T treatment is promising, it is still a long way away. McCarthy keeps his Buy rating on Gilead, noting the company's "multiple" catalysts in 2018-2019 along with its $32B cash cushion that can expand the pipeline through M&A.
05/02/18
LEER
05/02/18
NO CHANGE
Target $72
LEER
Market Perform
Gilead price target lowered to $72 from $80 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Gilead to $72 from $80 after the company reported Q1 results and produced the first "significant disappointment" of the large cap biotech earnings season. The analyst reiterates a Market Perform rating on the shares.
05/02/18
JEFF
05/02/18
NO CHANGE
Target $95
JEFF
Buy
Gilead turnaround thesis unchanged after Q1 results, says Jefferies
Jefferies analyst Michael Yee says that while Gilead Sciences last night didn't report the best quarter, the turnaround thesis remains unchanged. The results won't prove the thesis to bears, but Gilead's turnaround is underway and should play out over the next four quarters, Yee tells investors in a post-earnings research note. The stock, trading at an 11-12 times price-to-earnings ratio, is "cheap" and the worst is mostly behind the company, Yee adds. He keeps a Buy rating on Gilead with a $95 price target.
03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
BAYRY Bayer
$0.00

(0.00%)

04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
04/16/18
ARGS
04/16/18
DOWNGRADE
ARGS
Sell
Monsanto downgraded to Sell from Buy at Argus
Argus analyst Bill Selesky issued a double-notch downgrade on Monsanto (MON) to Sell from Buy after the U.S. Justice Department approved its acquisition by Bayer (BAYRY) last week. The analyst says the deal is expected to be further approved by Canadian and Mexican regulators and completed by the end of Q2. As part of the approval, the analyst points to the companies' pledge to sell additional assets even as Monsanto stock trades just below Bayer's acquisition price of $128 per share.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
CELG Celgene
$80.47

-0.88 (-1.08%)

04/30/18
RBCM
04/30/18
NO CHANGE
RBCM
Celgene weakness an overreaction, says RBC Capital
05/07/18
LEER
05/07/18
NO CHANGE
Target $115
LEER
Outperform
Celgene price target lowered to $115 from $123 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Celgene to $115 from $123 after the company announced Q4 results with a modest beat in revenues and pro forma EPS compared to consensus and significant delays in timing for two important development programs connected to ozanimod. Nonetheless, the analyst reiterates an Outperform rating, given the value of the company's existing products, and tangible late stage pipeline.
05/07/18
RBCM
05/07/18
DOWNGRADE
Target $118
RBCM
Outperform
Celgene downgraded to Outperform from Top Pick at RBC Capital
RBC Capital analyst Brian Abrahams downgraded Celgene to Outperform from Top Pick and lowered his price target for the shares to $118 from $120. The analyst continues to view the valuation as compelling, but he thinks other names offer more upside without more pipeline and Revlimid intellectual property visibility. Abrahams remains a buyer of Celgene shares.
05/04/18
PIPR
05/04/18
NO CHANGE
Target $95
PIPR
Neutral
Piper remains on sidelines after Celgene's 'surprisingly strong' Q1
Piper Jaffray analyst Christopher Raymond says that while he's encouraged by Celgene's "surprisingly strong" Q1 beat and "relatively timely" resubmission of ozanimod's multiple sclerosis new drug application, he remains concerned over the company's ability to diversify away from Revlimid. The analyst prefers to stay on the sidelines and keeps a Neutral rating on Celgene shares with a $95 price target.
VVUS VIVUS
$0.68

0.0221 (3.37%)

INSY Insys Therapeutics
$7.27

0.16 (2.25%)

03/09/18
PIPR
03/09/18
DOWNGRADE
Target $4
PIPR
Underweight
Insys Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Underweight and cut his price target for the shares to $4 from $5. The analyst sees "no basis in reality" for the company's guidance of relatively stable total sales in 2018 versus 2017 given the nature of the opioid crisis. Further, the weak rollout of Syndros "also does not inspire confidence" in the 2018 guidance, Amsellem tells investors in a research note.
07/21/17
JANY
07/21/17
NO CHANGE
Target $16
JANY
Buy
Subsys ANDA somewhat negative for Insys, but not unexpected, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA's Paragraph IV certifications list earlier this week showed that Insys had received an ANDA filing for Subsys on May 22, which he views as "somewhat negative," but also "not unexpected." While the ANDA raises the possibility of a generic sooner rather than later, Trbovich sees no risk for a generic Subsys until 2020 at the earliest and thinks the company's patents could prevent generic entry until as late as 2030. He keeps a Buy rating and $16 fair value estimate on Insys shares.
BIIB Biogen
$277.68

-3.69 (-1.31%)

04/26/18
CANT
04/26/18
NO CHANGE
Target $272
CANT
Neutral
Biogen price target lowered to $272 from $289 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Biogen to $17 and reiterates a Neutral rating on the shares following Tuesday's Q1 results. The analyst remains concerned that the company's "out-year growth prospects are too heavily leveraged to the successful development of assets for which significant de-risking may need to occur." Further, the Biogen's multiple sclerosis franchise will continue to face competition, Tanner tells investors in a research note.
05/02/18
SBSH
05/02/18
NO CHANGE
Target $290
SBSH
Neutral
Biogen price target lowered to $290 from $360 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen to $290 saying Tecfidera "is an unanswered question and a big risk to the stock." The analyst is unsure what the generic Gilenya impact will be on Tecfidera. Biogen shares may not be at a bad entry point for long-term investors, but "we don't think this is where people need to be over the next year," Karnauskas tells investors in research note. She believes the key issue for the shares is the Alzheimer's program and expects data late in 2019 or early 2020. The analyst keeps a Neutral rating on Biogen.
04/25/18
04/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he is increasingly comfortable with Alphabet's positioning in digital media relative to Facebook (FB), given Alphabet's private relationship with consumers and the high utility and durability of Google's core business. 2. Verizon (VZ) upgraded to Buy from Hold at SunTrust and to Buy from Neutral at UBS. 3. Disney (DIS) upgraded to Market Perform from Underperform at BMO Capital with analyst Daniel Salmon saying the risk-reward on the stock is now more balanced, while its leading portfolio remains a long-term attraction. 4. Biogen (BIIB) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney saying he believes the shares are "too cheap" and its MS business appears more stable than he had been concerned about. 5. PulteGroup (PHM) upgraded to Buy from Neutral at B. Riley FBR and to Buy from Neutral at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
04/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Terence Flynn saying pipeline and balance sheet optionality are taking longer to materialize than expected but valuation reflects limited value to Aducanumab or Biogen's Phase 2 neuro pipeline. 2. GrubHub (GRUB) downgraded to Neutral on valuation at Roth Capital with analyst Darren Aftahi citing valuation. 3. Paccar (PCAR) downgraded to Sector Perform from Outperform at RBC Capital and to Neutral from Buy at BofA/Merrill. 4. Caterpillar (CAT) downgraded to Neutral from Outperform at Daiwa. 5. Edwards Lifesciences (EW) downgraded to Market Perform from Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$35.67

-0.01 (-0.03%)

04/16/18
NORL
04/16/18
NO CHANGE
NORL
Outperform
Pfizer appears to be BioLife Solutions customer, says Northland
Northland analyst Suraj Kalia believes Pfizer (PFE) has never publicly announced itself as a customer of BioLife Solutions (BLFS), but a link to a presentation apparently made at the AAPS conference seems to highlight Pfizer' use of BioLife's CryoStor cryopreservation medium in its CAR-T program. Kalie noted this is the first time he has learned of Pfizer being a customer and of the use of BioLife's CryoStor being used in allogeneic CAR-T applications, both of which he finds interesting. Kalia has an Outperform rating on BioLife.
05/15/18
LEER
05/15/18
NO CHANGE
Target $121
LEER
Outperform
Sarepta price target raised to $121 from $88 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta (SRPT) to $121 from $88, while reiterating an Outperform rating on the shares. The analyst notes that Sarepta is one of three companies developing microdystrophin gene therapy for Duchenne muscular dystrophy, in competition with Pfizer (PFE) who acquired Bamboo, and Solid Biosciences (SLDB). With Solid's clinical hold still in place, Sarepta could potentially be first-to-market, and is expected to report the first clinical data for a micro-dystrophin candidate at their R&D day on June 19, he adds.
05/16/18
MSCO
05/16/18
NO CHANGE
Target $200
MSCO
Overweight
Epogen biosimilar should have little impact on Amgen, says Morgan Stanley
After the FDA approved Retacrit, Pfizer's (PFE) biosimilar version of Amgen's (AMGN) Epogen, Morgan Stanley analyst Matthew Harrison said he does not see significant impact to his forecasts due to the news, noting that Amgen has already discounted Epogen net selling price significantly to secure an extended supply agreement with DaVita (DVA). Amgen renegotiated the supply agreement in early 2017 and the vast majority of Epogen volume is from DaVita, added Harrison, who maintains an Overweight rating and $200 price target on Amgen shares.
04/19/18
04/19/18
NO CHANGE

BTIG says Allergan may be interested in Shire after insufficient Takeda offers
BTIG analyst Timothy Chiang noted that Shire (SHPG) is trading higher after news that at least one other company other than Takeda (TKPYY) is interested in acquiring Shire, and naming Allergan (AGN) as one of those possible suitors. Chiang also believes that other companies, such as Pfizer (PFE), could entering into the bidding for Shire. BTIG maintained a Buy rating and $195 price target on Shire shares.
VRX Ticker changed BHC
$22.17

0.08 (0.36%)

05/15/18
MZHO
05/15/18
UPGRADE
MZHO
Buy
Valeant upgraded to Buy from Neutral at Mizuho
05/14/18
BMOC
05/14/18
NO CHANGE
Target $20
BMOC
Market Perform
Valeant price target raised to $20 from $17 at BMO Capital
BMO Capital analyst Gary Nachman raised his price target on Valeant to $20, saying the company's "impressive" Q1 results demonstrate "good returns" on some of its strategic investments. Nachman also raised his FY18 EPS target to $3.42 from $3.12 to reflect the company's raised FY18 guidance. The analyst keeps his Market Perform rating amid continued uncertainty about sustainability of certain revenue drivers and potential contribution from its "key new product launches".
05/15/18
05/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Outperform from Market Perform at Telsey Advisory. 2. CBS (CBS) upgraded to Outperform from Market Perform at Bernstein with the firm saying it views the probability of a CBS-Viacom (VIAB) re-merger as close to zero, for many years to come. 3. Ulta Beauty (ULTA) upgraded to Outperform from Perform at Oppenheimer with analyst Rupesh Parikh saying he still sees the potential for more gains and outperformance from current levels. 4. Valeant (VRX) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying adjusting individual product growth estimates has made her more constructive on Valeant's turnaround story. 5. Scotts Miracle-Gro (SMG) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying he believes the bottom in the stock price has been reached, leading to its usual "counter seasonal trend of outperformance" given that the stock has outperformed the S&P500 from June to January in the past 11 of 15 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/23/18
09/23
04:55
09/23/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CMCSA

Comcast

$37.91

0.1 (0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

14:32
09/22/18
09/22
14:32
09/22/18
14:32
Periodicals
Comcast outbids Fox in battle for Sky, Reuters reports »

Comcast (CMCSA; CMCSK)…

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$43.97

-0.23 (-0.52%)

FOXA

21st Century Fox

$44.33

-0.26 (-0.58%)

SKYAY

Sky

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

, COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

13:36
09/22/18
09/22
13:36
09/22/18
13:36
Conference/Events
CoBiz Financial to host special shareholder meeting »

Special Shareholder…

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

AMRH

AMERI Holdings

$1.44

-0.04 (-2.70%)

13:30
09/22/18
09/22
13:30
09/22/18
13:30
Conference/Events
AMERI Holdings to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BRK.A

Berkshire Hathaway

$331,710.00

-1090 (-0.33%)

13:26
09/22/18
09/22
13:26
09/22/18
13:26
Periodicals
Berkshire Hathaway still looks underpriced, Barron's says »

Class A shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLGO

BioLargo

$0.00

(0.00%)

13:11
09/22/18
09/22
13:11
09/22/18
13:11
Conference/Events
BioLargo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.13

0.03 (0.21%)

12:56
09/22/18
09/22
12:56
09/22/18
12:56
Conference/Events
Citizens Community Bancorp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SF

Stifel Financial

$54.86

-0.78 (-1.40%)

12:50
09/22/18
09/22
12:50
09/22/18
12:50
Conference/Events
Stifel Financial to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBCT

People's United

$17.94

-0.055 (-0.31%)

, FBNK

First Connecticut

$30.95

0.1 (0.32%)

12:47
09/22/18
09/22
12:47
09/22/18
12:47
Conference/Events
First Connecticut to host special shareholder meeting »

Special shareholder…

PBCT

People's United

$17.94

-0.055 (-0.31%)

FBNK

First Connecticut

$30.95

0.1 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 18

    Oct

ASPS

Altisource

$34.10

-0.09 (-0.26%)

12:44
09/22/18
09/22
12:44
09/22/18
12:44
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, CSCO

Cisco

$48.51

0.77 (1.61%)

12:36
09/22/18
09/22
12:36
09/22/18
12:36
Periodicals
Apple, Microsoft among stocks with solid dividends, Barron's says »

Technology stocks are not…

AAPL

Apple

$217.65

-2.35 (-1.07%)

CSCO

Cisco

$48.51

0.77 (1.61%)

IBM

IBM

$151.29

0.12 (0.08%)

MSFT

Microsoft

$114.70

1.13 (0.99%)

ORCL

Oracle

$51.08

0.65 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 10

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

CAT

Caterpillar

$156.39

0.38 (0.24%)

, AMAT

Applied Materials

$39.62

0.22 (0.56%)

12:28
09/22/18
09/22
12:28
09/22/18
12:28
Periodicals
Caterpillar, KeyCorp among stocks to buy as bond yields rise, Barron's says »

As the economy improves,…

CAT

Caterpillar

$156.39

0.38 (0.24%)

AMAT

Applied Materials

$39.62

0.22 (0.56%)

BWA

BorgWarner

$45.24

-0.53 (-1.16%)

KEY

KeyCorp

$20.78

0.02 (0.10%)

PH

Parker-Hannifin

$190.52

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 18

    Oct

  • 25

    Oct

  • 30

    Oct

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

, ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

10:34
09/22/18
09/22
10:34
09/22/18
10:34
Periodicals
'Good time' to think about device markers, Barron's says »

Medical technology stocks…

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

TLRY

Tilray

$123.16

-53.365 (-30.23%)

10:20
09/22/18
09/22
10:20
09/22/18
10:20
Periodicals
Marijuana stocks 'the new Bitcoin,' Barron's says »

Led by Tilray, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, WMT

Walmart

$95.85

0.1 (0.10%)

09:05
09/22/18
09/22
09:05
09/22/18
09:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$217.65

-2.35 (-1.07%)

WMT

Walmart

$95.85

0.1 (0.10%)

DE

Deere

$152.82

-1.24 (-0.80%)

AGCO

Agco

$60.24

-0.9 (-1.47%)

ADM

Archer Daniels

$50.33

(0.00%)

MOS

Mosaic

$32.33

0.02 (0.06%)

CF

CF Industries

$52.82

-0.48 (-0.90%)

SPWR

SunPower

$7.88

-0.18 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 15

    Nov

  • 03

    Mar

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/22/18
09/22
04:55
09/22/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.